340B and Drug Pricing Archives

340B and Drug Pricing, Medicare

America’s Essential Hospitals Responds to Proposed OPPS Rule from CMS

July 2, 2026

340B and Drug Pricing, Medicaid

On the Hill: Busy Week as July 4 Recess Looms

June 30, 2026

340B and Drug Pricing

Two Timely Updates on the 340B Drug Pricing Program

June 26, 2026

340B and Drug Pricing

America’s Essential Hospitals Responds to Sen. Cassidy’s 340B Discussion Draft

June 25, 2026

340B and Drug Pricing

Association Responds to Eli Lilly’s Targeted 340B Pricing Suspension

June 23, 2026

340B and Drug Pricing, Health Care Reform

Eye on Advocacy: Designation Push Continues, 340B Under Scrutiny

May 15, 2026

340B and Drug Pricing

Association Responds to 340B Rebate Model Information Collection Request

April 28, 2026

340B and Drug Pricing

Association Responds to 340B Rebate Model Request for Information

April 21, 2026

340B and Drug Pricing

Court Ruling Authorizes Further Discounts on 340B Drugs

April 9, 2026

340B and Drug Pricing

Administration Proposes to Cut FY 2027 HHS Budget

April 8, 2026

340B and Drug Pricing

On the Hill: Nearly 100 Bipartisan House Members Urge No Federal Funds for 340B Rebate Model

March 31, 2026

340B and Drug Pricing

On the Hill: House 340B Rebate Letter, E&C Subcommittee Hearings

March 17, 2026

340B and Drug Pricing

Association to HRSA: Reject Novo Nordisk Claims Reporting Changes

March 10, 2026

340B and Drug Pricing

Federal Court Declares HRSA’s 340B Offsite Registration Policy Unlawful

March 9, 2026

340B and Drug Pricing

Association Highlights Improper Maximum Fair Price Denials

March 6, 2026

340B and Drug Pricing

Novo Nordisk Expands 340B Claims Reporting Requirements

March 4, 2026

340B and Drug Pricing

HRSA Extends 340B Rebate RFI After Association Advocacy, Details Future Scope

February 26, 2026

340B and Drug Pricing

Template for 340B Rebate Model RFI Comments

February 26, 2026

340B and Drug Pricing

Association Urges HRSA to Extend Rebate Model RFI Comment Period

February 20, 2026

340B and Drug Pricing

The Truth About the 340B Drug Pricing Program

February 19, 2026

340B and Drug Pricing

Protect the Safety Net by Protecting 340B

February 19, 2026

340B and Drug Pricing

HRSA Issues 340B Rebate Model Pilot Program RFI

February 17, 2026

340B and Drug Pricing

HHS Withdraws 340B Rebate Pilot

February 6, 2026

340B and Drug Pricing

Association Urges HRSA to Prohibit Claims Reporting Changes

February 3, 2026

Statement:

Proposed OPPS Rule from CMS

340B and Drug Pricing

Filter By:

America’s Essential Hospitals Responds to Proposed OPPS Rule from CMS

On the Hill: Busy Week as July 4 Recess Looms

Two Timely Updates on the 340B Drug Pricing Program

America’s Essential Hospitals Responds to Sen. Cassidy’s 340B Discussion Draft

Association Responds to Eli Lilly’s Targeted 340B Pricing Suspension

Eye on Advocacy: Designation Push Continues, 340B Under Scrutiny

Association Responds to 340B Rebate Model Information Collection Request

Association Responds to 340B Rebate Model Request for Information

Court Ruling Authorizes Further Discounts on 340B Drugs

Administration Proposes to Cut FY 2027 HHS Budget

On the Hill: Nearly 100 Bipartisan House Members Urge No Federal Funds for 340B Rebate Model

On the Hill: House 340B Rebate Letter, E&C Subcommittee Hearings

Association to HRSA: Reject Novo Nordisk Claims Reporting Changes

Federal Court Declares HRSA’s 340B Offsite Registration Policy Unlawful

Association Highlights Improper Maximum Fair Price Denials

Novo Nordisk Expands 340B Claims Reporting Requirements

HRSA Extends 340B Rebate RFI After Association Advocacy, Details Future Scope

Template for 340B Rebate Model RFI Comments

Association Urges HRSA to Extend Rebate Model RFI Comment Period

The Truth About the 340B Drug Pricing Program

Protect the Safety Net by Protecting 340B

HRSA Issues 340B Rebate Model Pilot Program RFI

HHS Withdraws 340B Rebate Pilot

Association Urges HRSA to Prohibit Claims Reporting Changes